GET DAILY SIGNALSAbbVie (ABBV): Immunology Momentum Poised to Drive Growth Into 2029
Key Takeaways
- Upcoming catalysts: FDA decisions on Rinvoq for vitiligo and alopecia areata, a subcutaneous Skyrizi induction approval for Crohn’s disease, and Phase 3 data in hidradenitis suppurativa (HS) and lupus could expand AbbVie’s immunology franchise in 2026 and 2027.
- Strategic positioning: Skyrizi and Rinvoq are on track to exceed $31 billion in combined 2026 sales, more than offsetting the ongoing erosion of legacy blockbuster Humira and anchoring management’s high-single-digit compound annual revenue growth target through 2029.
- Industry tailwinds and headwinds: Robust demand in immunology, neuroscience, and oncology supports growth, while new oral psoriasis competition from Johnson & Johnson’s Icotyde and low-single-digit pricing pressure present offsets.
- Macro sensitivity: Inflation Reduction Act (IRA) Medicare drug-price negotiations and payer rebates are a structural pricing headwind, with management flagging Vraylar pricing changes as a 2027 impact.
- Analyst sentiment: Wall Street consensus is broadly bullish, with an average 12-month price target near $310 and a range spanning roughly $237 to $350, according to recent polling of nearly 30 analysts.
- Key risks: Slower-than-expected new-indication uptake, intensified biosimilar and branded competition, and a continued drag in the aesthetics segment could temper the growth trajectory.
- For deeper detail on this ABBV ticker’s Major News, Today’s Price Move, Price Targets, and Earnings, explore the dedicated ABBV pages for a fuller picture of market activity and consensus data.
- For automated, AI-driven trade ideas across a range of assets, explore Trending AI Robots.
AbbVie’s Transition and Current Positioning
AbbVie has largely completed the difficult transition away from Humira, which lost U.S. exclusivity in 2023 and continues to decline in the face of biosimilar competition. The company’s medium-term positioning now rests on two immunology franchises with durable momentum. Skyrizi captured about half of new patient starts in inflammatory bowel disease (IBD), while Rinvoq is expanding into dermatology and rheumatology indications. Together, these products accounted for more than 47% of total revenue by mid-2026, and management expects combined sales above $31 billion this year. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The company is also laying the groundwork for its next immunology cycle. The roughly $10.9 billion acquisition of Apogee Therapeutics added zumilokibart, a late-stage anti-IL-13 (interleukin-13) antibody targeting atopic dermatitis, positioning AbbVie to compete with the category-leading Dupixent. Beyond immunology, a growing neuroscience portfolio led by Vraylar, Ubrelvy, Qulipta, and the newly approved Parkinson’s therapy Juvmo provides diversification, with management guiding the Parkinson’s franchise toward more than $5 billion in peak sales.
Major Catalysts on the Horizon
Several regulatory and clinical milestones could reshape investor expectations over the next several quarters. The FDA is reviewing Rinvoq for vitiligo and alopecia areata, with a U.S. decision on vitiligo expected later in 2026 and on alopecia areata in early 2027; management estimates the two dermatology indications could add nearly $2 billion in combined peak sales. A subcutaneous induction approval for Skyrizi in Crohn’s disease is also anticipated, improving convenience and potentially accelerating patient-share gains in 2027. From what I see, these timelines are worth monitoring closely.
In the pipeline, Phase 3 readouts for Rinvoq in hidradenitis suppurativa and systemic lupus erythematosus, along with lutikizumab data in HS, represent the next wave of label expansion. In oncology, positive Phase 3 results for etentamig in multiple myeloma have supported a U.S. regulatory submission, with a decision expected in 2027. Analyst ratings have trended more optimistic, with firms such as Morgan Stanley, Wells Fargo, and Leerink Partners raising price targets in recent months, reflecting growing confidence in the growth trajectory. I’m watching this closely with help from Tickeron’s AI Trend Prediction Engine for additional context on momentum.
Industry and Macroeconomic Influences
AbbVie’s trajectory is shaped by a mix of secular demand and policy-driven pricing pressure. Immunology markets for conditions such as atopic dermatitis and asthma are growing 15% to 20% annually, providing a favorable demand backdrop. At the same time, the Inflation Reduction Act’s Medicare drug-price negotiation framework introduces a structural pricing headwind, with management highlighting Vraylar pricing changes as a 2027 impact and an ongoing dispute over Botox’s eligibility for negotiation.
Interest rates and inflation affect AbbVie primarily through capital-allocation and valuation channels rather than direct demand, given the relatively inelastic nature of many specialty pharmaceuticals. However, the aesthetics segment, which has seen softer dermal filler demand, remains more exposed to discretionary consumer spending cycles. Geopolitical and supply-chain considerations are modest for a U.S.-centric specialty portfolio, though foreign-exchange movements can influence reported revenue.
2026 Outlook and Longer-Term Themes
Looking toward 2026 and beyond, AbbVie’s guidance for approximately $67.8 billion in full-year revenue and adjusted earnings of $13.95 to $13.99 per share reflects continued double-digit growth from Skyrizi and Rinvoq. Management has pointed to high-single-digit compound annual revenue growth through 2029, supported by a pipeline with no major loss-of-exclusivity events expected to materially disrupt the business this decade.
Longer-term, investors will watch whether combination immunology regimens built around Skyrizi with ABBV-382 and ABBV-701 can deliver best-in-class, durable remission in IBD, and whether the oncology pipeline—including etentamig and Epkinly—can scale into meaningful revenue contributors. Capital allocation priorities remain balanced, with a 5.2% dividend increase to $1.82 per share and a focus on bolt-on acquisitions in immunology, neuroscience, oncology, and obesity. Consensus analyst expectations, with an average price target near $310, suggest the market broadly anticipates continued execution, though regulatory outcomes and competitive dynamics remain key variables to monitor.
Adding Data-Driven Tools to My Research Process
In my view, incorporating AI-driven insights has become a useful complement to traditional fundamental analysis. One tool I turn to regularly is Tickeron’s AI Trend Prediction Engine, which helps assess whether a stock may move bullish, bearish, or sideways over the coming week or month. It offers searchable prediction categories, historical context, and alert-oriented functionality that can support timely decision-making when tracking names like ABBV. This adds a quantitative layer without replacing core research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ABBV saw its Stochastic Oscillator recovers from the overbought zone
The Stochastic Oscillator for ABBV moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 69 similar instances where the indicator exited the overbought zone. In 35 of the 69 cases the stock moved lower. This puts the odds of a downward move at 51%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ABBV moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 17 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.
The Moving Average Convergence Divergence Histogram (MACD) for ABBV turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 20 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 42%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABBV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
ABBV broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ABBV as a result. In 46 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
Following a +3.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABBV advanced for three days, in 217 of 356 cases, the price rose further within the following month. The odds of a continued upward trend are 61%.
The Aroon Indicator entered an Uptrend today. In 224 of 351 cases where ABBV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 1 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ABBV's P/B Ratio (-86.736) is very low in comparison to the industry average of (-1.360). ABBV has a moderately high P/E Ratio (82.291) as compared to the industry average of (21.695). Projected Growth (PEG Ratio) (0.544) is also within normal values, averaging (5.738). Dividend Yield (0.024) settles around the average of (0.038) among similar stocks. ABBV's P/S Ratio (7.231) is slightly higher than the industry average of (4.033).
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. ABBV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a research-based pharmaceutical company
Industry PharmaceuticalsMajor
Advertisement